XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company dedicated to developing innovative therapies for patients suffering from gout and progressive kidney diseases, particularly those influenced by aberrant purine and uric acid metabolism. Headquartered in Calgary, Alberta, Canada, the company focuses on addressing significant unmet medical needs within these therapeutic areas.

The company's pipeline includes several drug candidates targeting xanthine oxidase to reduce uric acid production. Its lead program, XRx-026 (XORLO™), is a proprietary oral oxypurinol formulation in late-stage development for allopurinol-intolerant gout, with an NDA filing anticipated. Other key programs include XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney injury associated with respiratory virus infections, and XRx-225 for Type 2 Diabetic Nephropathy. XORTX recently expanded its kidney disease portfolio through the acquisition of the VB4-P5 renal anti-fibrotic program.

Recent corporate activities include meeting Nasdaq continued listing requirements and the closing of the acquisition of the Vectus kidney anti-fibrotic asset in April 2026. The company also enacted a 1-for-5 share consolidation in April 2026. Dr. Allen Davidoff serves as the founder and CEO, leading an experienced management team focused on advancing the company's pipeline towards commercialization.